Novo’s Ozempic scores major win with heart-helping FDA approval. Is Rybelsus next?
After racing out to a fast start in its first year on the market, Novo Nordisk’s GLP-1 diabetes superstar Ozempic is already proving a darling for the Danish drugmaker. Now, a heart-helping FDA approval will likely spell even more success for the standout––and bodes well for Novo’s other much-touted diabetes launch. The FDA approved Ozempic to reduce the… Read More »
